个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Cheng, Y.[1] * ; Wang, J.[2] ; Yao, W.[3] ; Yu, Y.[4] ; Zang, A.[5] ; Cao, L.[6] ; Lv, D.[7] ; Li, S.[8] ; Meng, Z.[9] ; Zhang, J.[10] ; Guo, Q.[11] ; Huang, D.[12] ; Liu, A.[13] ; Liu, J.[14] ; Mao, W.[15] ; Tang, K.[16] ; Zhang, Y.[17] ; Chen, E.[18] ; Wang, Z.[19] ; Zheng, J.[20] ;
机构： [1]Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China [2]Chinese Acad Med Sci, Med Oncol, Canc Hosp, Beijing, Peoples R China [3]Sichuan Canc Hosp, Med Oncol, Chengdu, Peoples R China [4]Harbin Med Univ, Resp Med, Canc Hosp, Harbin, Peoples R China [5]Hebei Univ, Affiliated Hosp, Med Oncol, Baoding, Peoples R China [6]Anhui Prov Hosp, Resp Med, Hefei, Peoples R China [7]Taizhou Hosp Zhejiang Prov, Resp Med, Taizhou, Peoples R China [8]Fudan Univ, Resp Med, Huashan Hosp, Shanghai, Peoples R China [9]Nanjing Med Univ, Resp Med, Affiliated Huaian 1 Peoples Hosp, Huaian, Peoples R China [10]Southern Med Univ, Zhujiang Hosp, Med Oncol, Guangzhou, Peoples R China [11]Shandong Canc Hosp & Inst, Med Oncol, Jinan, Peoples R China [12]Tianjin Med Univ, Thorac Oncol, Canc Inst & Hosp, Tianjin, Peoples R China [13]Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China [14]Dalian Med Univ, Affiliated Hosp 1, Med Oncol, Dalian, Peoples R China [15]Southeast Univ, Sch Med, Med Oncol, Affiliated Jiangyin Hosp, Jiangyin, Peoples R China [16]Sun Yat Sen Univ, Affiliated Hosp 1, Pulm & Crit Care Med, Guangzhou, Peoples R China [17]Southeast Univ, Affiliated Nanjing Chest Hosp, Med Sch, Resp Med, Nanjing, Peoples R China [18]Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Resp Med, Hangzhou, Peoples R China [19]Yangzhou Univ, Affiliated Hosp, Med Oncol, Yangzhou, Jiangsu, Peoples R China [20]Wenzhou Cent Hosp, Resp Med, Wenzhou, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.10.598
ISSN：
基金：
AstraZeneca China
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Jilin Canc Hosp, Med Oncol, Changchun, Jilin, Peoples R China
推荐引用方式(GB/T 7714)：
Cheng Y.,Wang J.,Yao W.,et al.Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)[J].ANNALS OF ONCOLOGY.2023,34:S1673-S1673.doi:10.1016/j.annonc.2023.10.598.
APA：
Cheng, Y.,Wang, J.,Yao, W.,Yu, Y.,Zang, A....&Zheng, J..(2023).Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC).ANNALS OF ONCOLOGY,34,
MLA：
Cheng, Y.,et al."Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)".ANNALS OF ONCOLOGY 34.(2023):S1673-S1673

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号